Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Approved for Clinical Trials in China

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-04
Category: health
Source: The National Law Review

China's National Medical Products Administration (NMPA) has approved Kexing Biopharma's investigational anti-TL1A monoclonal antibody, GB20, for clinical trials in inflammatory bowel disease (IBD). GB20, developed using proprietary KX-BODY antibody technology, aims to suppress inflammation and delay fibrosis in IBD patients.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai